Houston, TXNCT05357794Now EnrollingIRB Ready

Mycosis Fungoides Clinical Trial in Houston, TX

Access cutting-edge mycosis fungoides treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by M.D. Anderson Cancer Center

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access mycosis fungoides specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mycosis fungoides treatment provided free

Apply for This Houston Location

Check if you qualify for this mycosis fungoides clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Mycosis Fungoides Study in Houston

To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Biopsy-confirmed mycosis fungoides in stage I-IV (APPENDICES 3 AND 4); the presence of Sezary cells in the blood is acceptable at original diagnosis or at enrollment into the protocol, as long as the patient has current mycosis fungoides in the skin and the sesary cells in peripheral blood are \< 1000 cells/ microlitre at the time of enrollment.
Participants with relapsed/ refractory mycosis fungoides expressing at least 1% CD30 are eligible.
Previous systemic anticancer therapy must have been discontinued at least 1 week before treatment
In the case of myelosuppressive chemotherapy treatment may start once counts have recovered including absolute WBC\> 1000, platelets\> 50K.
Topical or systemic steroids (equivalent to 10 mg/day of prednisone) may be considered if the dose of such steroids has been constant and their discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering, after discussion with the Principal Investigator.
18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 3 (APPENDIX 5)
No required wash-out period for prior therapies
HIV+ participants must be on stable antiretroviral treatment for 12 weeks before the first day of cycle 1 (C1D1), with CD4 count \>200 within the 7 days before C1D1.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Concurrent use of other systemic anticancer agents or treatments (including steroids unless adrenal insufficiency has been diagnosed) for mycosis fungoides or Sezary syndrome
Grade 2 or greater neuropathy
Severe renal impairment (creatinine clearance \[CrCL\] \<30 mL/min)
Moderate or severe hepatic impairment (Child-Pugh B or C; see APPENDIX 6 for ChildPugh classification chart)
Women of reproductive potential must have a negative serum ß human chorionic gonadotropin (ß-HCG) pregnancy test within 1 week of C1D1. They should discuss contraception with the treating provider. And agree to use adequate birth control measures (oral, implanted, or barrier methods) while on study Female participants of childbearing potential who are not abstinent and intend to be sexually active with a non sterilized male partner must use at least 1 highly effective method of contraception (Failure rate of \<1% per year when used consistently and correctly) throughout the total duration of the drug treatment and the drug washout period as determined by your physician. Non-sterilized male partners of a female participants of childbearing potential must use male condom plus spermicide throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female participants should also refrain from breastfeeding throughout this period. Highly effective contraceptive methods:
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation
intravaginal
transdermal
Progestogen-only hormonal contraception associated with inhibition of ovulation
Implantable progestogen-only hormonal contraception associated with inhibition of ovulation b
Intrauterine device (IUD)c
Intrauterine hormone-releasing system (IUS)c
Bilateral tubal occlusion
Surgical Sterilization
Receipt of systemic therapy for another primary malignancy (other than T-cell lymphoma). Participants with more than one type of lymphoma may be enrolled after discussion with the Principal Investigator
Underlying medical conditions including unstable cardiac disease, or other serious illness that would impair the ability of participants to undergo treatment
Any other medical history, including laboratory results, deemed by the Principal Investigator to be likely to interfere with participants participation in the study
Use of strong CYP3A4 inhibitors or inducers, or P-gp inhibitors, should be avoided given the potential effect on exposure to monomethyl auristatin E.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT05357794) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mycosis Fungoides Treatment Options in Houston, TX

If you're searching for mycosis fungoides treatment options in Houston, TX, this clinical trial (NCT05357794) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mycosis fungoides specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mycosis fungoides clinical trials near you to find additional studies recruiting in your area.

More Osteogenesis Imperfecta Trials in Houston, TX

See all osteogenesis imperfecta clinical trials recruiting in Houston — not just this study.

Browse Osteogenesis Imperfecta Trials in Houston →

Browse More Trials by Condition

Osteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX